Cheryl Gault, Director at Rapport Therapeutics, Inc. (RAPP), bought 35,714 shares at $27.28 ($974K) on 2026-10-22, disclosed to the SEC on 2026-10-22.
Director Cheryl Gault purchased $974k of RAPP stock at $27.28, marking the largest insider purchase in the company's history, signaling confidence during a steep price decline. This rare reversal amidst a net seller flow suggests insiders see value at current depressed levels.
RAPP is down 36.45% over the last 30 days and trades 50.17% below its 52-week high of $52.93, currently sitting at $26.38.
Insider cluster: This is the largest insider purchase ever recorded for RAPP; track this momentum as a potential signal. Sector context: Biotech industry net buyer flow is negative (-0.0053%) over the last 90 days, making this specific purchase stand out.
Short interest: The stock has a short interest of 10.54% of the float, indicating significant bearish sentiment that could pressure the price further.
Something here stands out, but not much.
| Filing → |
| RAPP | SELL | 2026-10-23 | $64K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $249K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |